Comparison of Doxorubicin and Cyclophosphamide Versus Single-Agent Paclitaxel As Adjuvant Therapy for Breast Cancer in Women With 0 to 3 Positive Axillary Nodes: CALGB 40101 (Alliance)

PURPOSE: Optimal adjuvant chemotherapy for early-stage breast cancer balances efficacy and toxicity. We sought to determine whether single-agent paclitaxel (T) was inferior to doxorubicin and cyclophosphamide (AC), when each was administered for four or six cycles of therapy, and whether it offered...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Shulman, Lawrence N., Berry, Donald A., Cirrincione, Constance T., Becker, Heather P., Perez, Edith A., O'Regan, Ruth, Martino, Silvana, Shapiro, Charles L., Schneider, Charles J., Kimmick, Gretchen, Burstein, Harold J., Norton, Larry, Muss, Hyman, Hudis, Clifford A., Winer, Eric P.
Natura: Artigo
Lingua:Inglês
Pubblicazione: American Society of Clinical Oncology 2014
Soggetti:
ORIGINAL REPORTS
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC4105484/
https://ncbi.nlm.nih.gov/pubmed/24934787
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2013.53.7142
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi